Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

Phase 4

Completed

• Conditions: Attention Deficit Disorder With Hyperactivity; Methylphenidate; Pharmacogenetics
• Interventions: Genetic: norepinephrine transporter polymorphism,

• Registration Number: NCT00757029
• Lead Sponsor: Hallym University Medical Center

Brief Summary

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10
• Primary Completion: 2008-08
• Study First Submitted: 2008-09-19
• Study First Submitted QC: 2008-09-19
• Study First Posted: 2008-09-22
• Study Completion: 2010-08
• Status Verified: 2010-12
• Last Update Submitted: 2011-10-04
• Last Update Posted: 2011-10-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• ADHD
• Physically healthy

Exclusion Criteria

• Neurological illness
• Concurrent additional psychiatric treatment
• < IQ 70
• Psychotic disorder
• Major mood disorder needed other psychiatric medication
• Significant suicidal ideation
• Pervasive developmental disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
open label	norepinephrine transporter polymorphism,	-

Primary Outcome Measures

Name	Time	Method
Korean ADHD Rating scale-parent version (KARS)	baseline,1,2,4,8 weeks

Secondary Outcome Measures

Name	Time	Method
Barkely side effect rating scale	1,2,4,8weeks

Trial Locations

Locations (1)

Hallym University Sacred Heart Hospital; 🇰🇷 Anyang, Gyeonggi-do, Korea, Republic of